Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
gene therapy
3
×
life sciences
national blog main
national top stories
3
×
new york blog main
san diego blog main
san francisco blog main
biotech
bluebird bio
clinical trials
deals
hemophilia
new york top stories
san diego top stories
san francisco top stories
vertex pharmaceuticals
adeno-associated virus
alexandria venture investments
alnylam pharmaceuticals
altitude life science ventures
ambys medicines
american society of gene and cell therapy
amicus therapeutics
ampio pharmaceuticals
angelman syndrome
arch venture partners
astellas pharma
athenex
atlas venture
audentes therapeutics
avidity biosciences
biomarin pharmaceutical
boston
boulder/denver blog main
boulder/denver top stories
boxer capital
centers for medicare & medicaid services
chris collins
What
long
3
×
drug
gene
help
therapy
ago
aren’t
bio
biotechs
considering
crude
cutting
data
despite
developers
diseases
drugs
dyne
early
edge
effects
encoded
expected
experimental
eyes
fda
genetic
having
humans
illumina’s
imminent
ipo
ipos
lasting
limited
limits
medicare
medicine
medicines
moves
Language
unset
Current search:
" national top stories "
×
" gene therapy "
×
long
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More